<DOC>
	<DOC>NCT01497145</DOC>
	<brief_summary>This is a multicenter, Randomized, Open-Label, Parallel, Comparative, Dose-Response Study to Evaluate the Efficacy and Safety study of KRN321 of subcutaneous injection in Adult Subjects with Low- or Intermediate-1-Risk Myelodysplastic Syndrome.</brief_summary>
	<brief_title>A Clinical Study of KRN321 in Adult Subjects With Myelodysplastic Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<criteria>IPSS low or intermediate1risk MDS diagnosed at enrollment Serum EPO concentration ≤ 500 mIU/mL Hemoglobin concentration ≤ 9.0 g/dL at the screening examinations Previous bone marrow or hematopoietic stem cell transplantation History of pure red cell aplasia Cardiac conditions including angina pectoris, congestive heart failure, uncontrolled arrhythmia and hypertension Those who have increased risk of thrombosis during the study Uncontrolled diabetes mellitus Concurrent active infection or chronic inflammatory disease Other causes of anemia Previous or concurrent active malignancies other than MDS</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>